BAUSCH HEALTH COS INC (BHC) Fundamental Analysis & Valuation
NYSE:BHC • CA0717341071
5.33 USD
-0.02 (-0.37%)
Last: Mar 10, 2026, 09:54 AM
This BHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
BHC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is cheap, but on the other hand it scores bad on growth.
1. BHC Profitability Analysis
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC reported 4 times negative net income.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 0.60%, BHC is doing good in the industry, outperforming 79.79% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 7.78%, BHC belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
- BHC had an Average Return On Invested Capital over the past 3 years of 6.89%. This is significantly below the industry average of 13.09%.
- The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- Looking at the Profit Margin, with a value of 1.53%, BHC is in the better half of the industry, outperforming 79.79% of the companies in the same industry.
- BHC has a better Operating Margin (21.28%) than 88.60% of its industry peers.
- BHC's Operating Margin has improved in the last couple of years.
- BHC's Gross Margin of 70.65% is fine compared to the rest of the industry. BHC outperforms 77.72% of its industry peers.
- In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. BHC Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BHC is creating some value.
- Compared to 1 year ago, BHC has more shares outstanding
- The number of shares outstanding for BHC has been increased compared to 5 years ago.
- Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
- BHC has an Altman-Z score of 0.28. This is a bad value and indicates that BHC is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of BHC (0.28) is comparable to the rest of the industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- The Debt to FCF ratio of BHC (21.00) is better than 75.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.28 |
ROIC/WACC1.2
WACC6.5%
2.3 Liquidity
- BHC has a Current Ratio of 1.47. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.47, BHC is doing worse than 70.47% of the companies in the same industry.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- BHC's Quick ratio of 1.08 is on the low side compared to the rest of the industry. BHC is outperformed by 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. BHC Growth Analysis
3.1 Past
- BHC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
- Measured over the past years, BHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.13% on average per year.
- Looking at the last year, BHC shows a small growth in Revenue. The Revenue has grown by 6.66% in the last year.
- The Revenue has been growing slightly by 5.04% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -1.34% on average over the next years.
- Based on estimates for the next years, BHC will show a decrease in Revenue. The Revenue will decrease by -0.94% on average per year.
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue Next Year4.35%
Revenue Next 2Y2.09%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. BHC Valuation Analysis
4.1 Price/Earnings Ratio
- BHC is valuated cheaply with a Price/Earnings ratio of 1.41.
- Based on the Price/Earnings ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.45, BHC is valued rather cheaply.
- BHC is valuated cheaply with a Price/Forward Earnings ratio of 1.22.
- Based on the Price/Forward Earnings ratio, BHC is valued cheaply inside the industry as 98.96% of the companies are valued more expensively.
- BHC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.65.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.41 | ||
| Fwd PE | 1.22 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BHC is valued cheaper than 94.82% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.99 | ||
| EV/EBITDA | 6.34 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -5.25% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
5. BHC Dividend Analysis
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BHC Fundamentals: All Metrics, Ratios and Statistics
NYSE:BHC (3/10/2026, 9:54:04 AM)
5.33
-0.02 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners44.72%
Inst Owner Change-1.85%
Ins Owners11.42%
Ins Owner Change10.17%
Market Cap1.98B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (39.4%)
Short Float %1.72%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)-0.23%
PT rev (3m)1.85%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)0.22%
EPS NY rev (1m)1.65%
EPS NY rev (3m)1.71%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.41 | ||
| Fwd PE | 1.22 | ||
| P/S | 0.19 | ||
| P/FCF | 1.99 | ||
| P/OCF | 1.41 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.34 |
EPS(TTM)3.77
EY70.73%
EPS(NY)4.36
Fwd EY81.8%
FCF(TTM)2.68
FCFY50.28%
OCF(TTM)3.78
OCFY70.88%
SpS27.7
BVpS-1.5
TBVpS-44.44
PEG (NY)0.09
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.28 |
F-Score6
WACC6.5%
ROIC/WACC1.2
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y15.65%
EPS Next 2Y3.9%
EPS Next 3Y-5.25%
EPS Next 5Y-1.34%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.35%
Revenue Next 2Y2.09%
Revenue Next 3Y-2.16%
Revenue Next 5Y-0.94%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.11%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.